Inicio › Cáncer de pulmón de células no pequeñas › Ohio

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Ohio

123 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Ohio.

Ciudades en Ohio

Texto oficial del estudio (inglés)

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Dayton Physician's Network, Dayton

ReclutandoFase 3

Edades de 18 a 100 · Todos los sexos · Actualizado el 13 nov 2026 · NCT05920356

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center, Cleveland

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07111520

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

University Hospitals Cleveland Medical Center, Cleveland
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07100080

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
University Hospitals Cleveland Medical Center, Cleveland
University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06758401

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Aultman Health Foundation, Canton
Miami Valley Hospital South, Centerville
Ohio State University Comprehensive Cancer Center, Columbus
y 5 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Cleveland Clinic Akron General, Akron
Strecker Cancer Center-Belpre, Belpre
Aultman Health Foundation, Canton
y 34 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04267848

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06345729

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Cleveland Clinic, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04886804

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Cleveland Clinic, Cleveland

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06868485

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Local Institution - 0438, Sandusky

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07680790

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

University of Cincinnati Medical Center ( Site 0119), Cincinnati

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06623422

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

The James Cancer Hospital and Solove Research Institute, Columbus

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07541170

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0486, Centerville
University of Cincinnati Medical Center, Cincinnati
Local Institution - 0512, Zanesville

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06561386

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
y 5 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07144280

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

ProMedica Flower Hospital, Sylvania

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07388524

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Ohio State University, Columbus

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06793215

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Akron General Medical Center, Akron
The Christ Hospital, Cincinnati
University Hospitals Cleveland Medical Center, Cleveland
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07361497

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06465069

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Aultman Hospital, Canton
Miami Valley Hospital South, Centerville
Fairview Hospital, Cleveland
y 4 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06890598

Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

University Hospitals Seidman Cancer Center, Cleveland
Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07746388

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Indu and Raj Soin Medical Center, Beavercreek
Strecker Cancer Center-Belpre, Belpre
Saint Elizabeth Boardman Hospital, Boardman
y 11 más

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06418204

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

The Ohio State University (OSU) Wexner Medical Center, Columbus

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06400472

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Miami Valley Hospital South, Centerville
USO - Oncology Hematology Care, Cincinnati
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06119581

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland
The Jame Outpatient Care West Campus, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07397338

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

Investigator Site, Canton

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07688577

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT03191149

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Gabrail Cancer & Research Center, Canton

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05856981

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

UH Cleveland Medical Center, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07542704

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

The Christ Hospital Physicians - Mt. Auburn, Cincinnati
Ohio State University CRS, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06303505

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07293247

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University Hospitals Cleveland Medical Center, Cleveland

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06667908

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Cleveland Clinic, Taussig Cancer Institute, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06720987

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Gabrail Cancer Center Research, Canton
The Christ Hospital Cancer Center, Cincinnati
University of Cincinnati Medical Center, Cincinnati
y 5 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT06712316

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

University of Cincinnati Medical Center, Cincinnati
University Hospitals Cleveland Medical Center, Cleveland

ReclutandoFase 3

Edades de 18 a 90 · Todos los sexos · Actualizado el 2 nov 2026 · NCT06745908

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Ohio State University Hospitals, Columbus

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07185997

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Local Institution - 007-893-B, Cincinnati
USOR - Oncology Hematology Care - Blue Ash, Cincinnati
Local Institution - 007-893-C, Cincinnati
y 5 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT04613596

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015), Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT04165070

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT04165798

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

University Hospitals Cleveland, Cleveland
The James Cancer Hospital and Solove Research Institute, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT05098132

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.